ADAPTIMMUNE THERAPEUTICS PLC

ADAPY ·Healthcare, Drug Manufacturers - General
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2016 FY2015 FY2014
Operating Activities
Net Income $-71.6M $-22.1M $-11.6M
Depreciation & Amortization
Depreciation $3.1M $705.0K $240.0K
Amortization $160.0K $30.0K $0
Stock-Based Compensation $8.8M $7.1M $332.0K
Net Cash from Operating Activities $-48.2M $-29.7M $36.8M
Investing Activities
Capital Expenditures $11.5M $5.1M $1.4M
Business Acquisitions
Net Cash from Investing Activities $17.8M $-58.8M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $17.0K $274.9M
Net Change in Cash $-36.0M $177.9M
Free Cash Flow $-59.7M $-34.7M $35.5M
← Newer Page 2 of 2 Older →